BB30230: Cancer therapeutics
[Page last updated: 04 August 2021]
| Academic Year: | 2021/2 |
| Owning Department/School: | Department of Biology & Biochemistry |
| Credits: | 6 [equivalent to 12 CATS credits] |
| Notional Study Hours: | 120 |
| Level: | Honours (FHEQ level 6) |
| Period: |
|
| Assessment Summary: | CW 100% |
| Assessment Detail: |
|
| Supplementary Assessment: |
|
| Requisites: | Before taking this module you are advised to take BB20023 |
| Aims: | To provide students with:
* A thorough understanding of the scientific basis underlying the principles and practice of cancer therapeutics * A critical overview of the biology behind the development and evaluation of current and emerging treatments for cancer. |
| Learning Outcomes: | After taking this course the student should be able to:
* Demonstrate a thorough knowledge of the molecular and microenvironmental differences between cancer and normal tissues * Explain how these differences are exploited in drug design for cancer treatment * Critically evaluate current and emerging therapies against cancer. |
| Skills: | Learning and studying T/F/A, information handling and retrieval T/F/A, working independently T/F, written communication T/F/A, oral communication T/F/A. |
| Content: | Molecular and cellular cancer pathways associated with the tumour microenvironment or growth, which underpin current cancer treatments including;
* Genetic screening * Radiotherapy, chemotherapy and adjuvant therapies * Emerging therapies such as immunotherapy, angiotherapy and other small molecule therapies based on the translation of innovative cancer biology research into lead and preclinical stage drug candidates. |
| Programme availability: |
BB30230 is Optional on the following programmes:Department of Biology & Biochemistry
|
Notes:
|